Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Shire shares hit reverse gear after it cautions on earnings

Shire remains something of a contradiction in terms of general market attitude - said Richard Hunter, head of markets at Interactive Investor
Shire shares hit reverse gear after it cautions on earnings
The company signposted that costs may rise in 2018

Shares in speciality pharma giant Shire PLC (LON:SHP) nudged lower in afternoon trade as analysts got out the red pen in the wake of annual results.

While the figures themselves were slightly ahead of consensus, the outlook was a little weaker than number crunchers had been expecting.

READ: Shire backtracks on a key revenue target and says it plans to separate businesses

US outfit Jefferies said its EPS forecasts would require “trimming”, though it maintained its ‘buy’ recommendation and £49 a share price target.

Share price almost a third in a year

At 1.30pm, the stock, off almost a third in the last 12 months, was changing hands for £31.44, down 1.18% on the day.

Earlier, Shire said total revenues were up 32% at US$15.2bn, aided by a first full year contribution from Baxalta, which it bought for US$32bn. Net income was US$4.3bn.

However, it warned that 2018 earnings could undershoot because of higher costs.

“Shire remains something of a contradiction in terms of general market attitude,” said Richard Hunter, head of markets at Interactive Investor.

“The shares have lost some 30% over the last year as concerns persist, as compared to a drop of 0.6% for the wider FTSE100.

“Despite this underperformance the shares are clearly well regarded as a potential growth story, with the market consensus of the company as a strong buy having been in place for some time.”

View full SHP profile View Profile

Shire Plc Timeline

Related Articles

cancer cells in blood
July 17 2018
It’s been a tricky year for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
DNA sequence
July 12 2018
The cell therapy specialist also reported there had been industry interest around its main programmes

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use